Psychological and quality of life changes in patients using GLP-1 analogues

Abstract Aims Using psychological and quality of life assessment tools, we prospectively studied changes in health-related quality of life and emotional well-being in patients who had commenced GLP-1 analogue therapy (exenatide) and compared them with new insulin starters. Methods Two matched groups...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes and its complications 2011-07, Vol.25 (4), p.244-246
Main Authors: Grant, Paul, Lipscomb, David, Quin, John
Format: Article
Language:English
Subjects:
Aged
Anxiety - prevention & control
Body Mass Index
Depression - prevention & control
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - psychology
Endocrinology & Metabolism
Exenatide
Female
GLP-1 analogues
Glucagon-Like Peptide 1 - adverse effects
Glucagon-Like Peptide 1 - analogs & derivatives
Glucagon-Like Peptide 1 - therapeutic use
Glycated Hemoglobin A - analysis
Health-related quality of life
Humans
Hyperglycemia - prevention & control
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Incretins - adverse effects
Incretins - therapeutic use
Male
Middle Aged
Patient Satisfaction
Peptides - adverse effects
Peptides - therapeutic use
Psychiatric Status Rating Scales
Quality of Life
Type 2 diabetes
United Kingdom
Venoms - adverse effects
Venoms - therapeutic use
Weight Loss - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aims Using psychological and quality of life assessment tools, we prospectively studied changes in health-related quality of life and emotional well-being in patients who had commenced GLP-1 analogue therapy (exenatide) and compared them with new insulin starters. Methods Two matched groups of patients with type 2 diabetes who had suboptimal glycaemic control on oral medication were assessed using a battery of well-validated psychological and quality of life tests at baseline, prior to commencement of treatment and then again after 6 months of continuous therapy, along with body mass index (BMI) and hemoglobin A1c (HbA1c) measurements. Results In the exenatide-treated patient group ( n =71), treatment satisfaction was greater ( P
ISSN:1056-8727
1873-460X
DOI:10.1016/j.jdiacomp.2011.03.002